{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:40:04Z","timestamp":1790732404180,"version":"4.1.0"},"reference-count":9,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T00:00:00Z","timestamp":1470268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The InSite trial is a prospective, multicenter study of sacral neuromodulation (SNM) therapy with the InterStim\u00ae System in subjects with overactive bladder (OAB). One of the primary aims of the study is to report on long\u2010term safety of the tined lead. This analysis provides detailed descriptions of device\u2010related adverse events (AEs) and surgical interventions to 12 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Analysis included those subjects who completed test stimulation with a tined lead, received a full implant, and reported device\u2010related AEs out to 12 months. A Clinical Events Committee (CEC) adjudicated AEs to 12 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Device\u2010related AEs occurred in 30% (82\/272) of subjects, with only one considered serious. Fifty\u2010six percent of the device\u2010related AEs occurred between implant and 3 months. The most frequent device\u2010related AEs were undesirable change in stimulation (12%, 32\/272); implant site pain (7%, 20\/272); and implant site infection (3%, 9\/272). Of the 26 events of implant site pain, 13 required surgical intervention, with only two resulting in explant. Ten subjects experienced 13 events of a surgical site infection (including an additional cellulitis), five of which resolved with antibiotics and eight required explantation. The overall surgical intervention rate was 13% with the most common reasons being pain at the surgical site (4%), lack\/loss of efficacy (4%), and infection (3%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although a 30% AE rate was reported, most AEs were minor and were resolved without surgical intervention. Surgical intervention was required in 13% of subjects, with the majority being revision or replacement. <jats:italic>Neurourol. Urodynam. 36:1136\u20131139, 2017<\/jats:italic>. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.23076","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T12:57:21Z","timestamp":1470315441000},"page":"1136-1139","source":"Crossref","is-referenced-by-count":52,"title":["Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients"],"prefix":"10.1002","volume":"36","author":[{"given":"Karen","family":"Noblett","sequence":"first","affiliation":[{"name":"University of California Riverside California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Benson","sequence":"additional","affiliation":[{"name":"Sanford Health Sioux Falls South Dakota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Kreder","sequence":"additional","affiliation":[{"name":"University of Iowa Iowa City Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,4]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68558-8"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67558-1"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200101000-00004"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181cf8ed0"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.01.076"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22544"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22707"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0000000000000183"},{"key":"e_1_2_5_10_1","unstructured":"Medtronic InterStim Therapy Clinical Summary.http:\/\/manuals.medtronic.com\/wcm\/groups\/mdtcom_sg\/@emanuals\/@era\/@neuro\/documents\/documents\/contrib_198621.pdf.2014."}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.23076","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.23076","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.23076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:48:26Z","timestamp":1696355306000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.23076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1002\/nau.23076"],"URL":"https:\/\/doi.org\/10.1002\/nau.23076","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,4]]}}}